SINGLE-CENTRE/OPEN/RANDOMIZED, 24 WEEKS, PHASE I CLINICAL TRIAL OF ANCILLA DOMINI KDS AGONIST 234-A AND ANCILLA DOMINI KDS AGONIST- 233-B ON KIDNEY DISEASES

Single-Centre/Open/Randomized 24 Weeks Phase I Clinical Trial Of Ancilla Domini CHoTA-KDs 234-A Inverse Transcription Therapeutics And CHoTA-KDs 233-B Inverse Transcription Therapeutics On Kidney Diseases

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

PACTR

Registry ID

PACTR202410587273157

Enrollment

Registered

2024-10-10

Start date

2024-11-11

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Disease

Interventions

Ancilla Domini CHoTTA KDS 234A

Ancilla Domini CHotta KDS 233B

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Adults 18+ years old 2. Male/Female 3. Residing in any part of Ghana 4. Open to all nationalities/race 5. People diagnosed of any type/stage of Kidney Diseases

Exclusion criteria

Exclusion criteria: 1. Children/under 18 years old 2. Pregnant/ Lactating Mothers

Design outcomes

Primary

Measure	Time frame
Both Ancilla Domini CHotta-KDS 234-A and Ancilla Domini CHotta-KDS 233-B shall normalize over 80% of Kidney Diseases.;Over 70% of deteriorations/complications of 80% of Kidney Diseases shall be halted/reversed/prevented	—

Secondary

Measure	Time frame
Over 80% of Kidney Diseases shall be treated with only Ancilla Domini Cellular Holistic Transcription Therapeutics Agonist-KDS (either CHotta-KDS 234-A or CHotta-KDS 234-B) as a mono-therapy;All research candidates shall experience 99.9% safety from the Kidney Diseases Investigational Medicinal Product - Ancilla Domini CHoTTA-KiDs	—

Countries

Ghana

Contacts

Public ContactGeoffrey Alee

Public Relations Executive

denudation2015@gmail.com+2347041388422

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026